Evidence map›Paper›PMID 42575974›Full record

ArticleNature microbiology2026

Combination therapy with broadly neutralizing antibodies, antiretroviral therapy and CCR5 blockade limits viral reservoir seeding in infant macaque model of HIV.

Jonah B Sacha, Tracy Ordonez, Shilpi Pandey, Gabriela Webb, Philip Barnette, Cleiton Pessoa, Matthew C Humkey, Jason Reed, Anden Morehead, Jennifer K Watanabe and 20 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Jonah B SachaOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA. sacha@ohsu.edu.ORCID http://orcid.org/0000-0002-7633-3122
Tracy OrdonezOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Shilpi PandeyOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Gabriela WebbOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Philip BarnetteOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0002-8985-6192
Cleiton PessoaOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Matthew C HumkeyOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Jason ReedOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Anden MoreheadOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.ORCID http://orcid.org/0009-0000-0731-2523
Jennifer K WatanabeCalifornia National Primate Research Center, Microbiology and Immunology, University of California, Davis, CA, USA.
Jodie L UsachenkoCalifornia National Primate Research Center, Microbiology and Immunology, University of California, Davis, CA, USA.
Shrivaas VijayanCalifornia National Primate Research Center, Microbiology and Immunology, University of California, Davis, CA, USA.ORCID http://orcid.org/0009-0003-9870-2982
Altair FazioOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Heather SidenerOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Anne D LewisOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.ORCID http://orcid.org/0000-0003-4059-7318
Gabrielle PastenkosCalifornia National Primate Research Center, Microbiology and Immunology, University of California, Davis, CA, USA.
Sohita OjhaOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Aaron Barber-AxthelmOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Bella SwanOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Rachele BochartOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Amarendra PeguVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Emily J FrayDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-5850-6237
Rachael M WoltersOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Janet D SilicianoDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-6712-3775
Robert F SilicianoHoward Hughes Medical Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-1764-1993
Scott G HansenOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Koen K A Van RompayCalifornia National Primate Research Center, Microbiology and Immunology, University of California, Davis, CA, USA.ORCID http://orcid.org/0000-0002-7375-1337
Ann J HessellOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA.
Nancy L HaigwoodOregon National Primate Research Center, Oregon Health & Science University, Portland, OR, USA. haigwoon@ohsu.edu.ORCID http://orcid.org/0000-0002-1477-9575

Funding

A nonhuman primate model of stem cell transplantation to understand determinants of post-transplant SIV clearanceR01AI129703 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SACHA, JONAH B. · 2017 to 2025
$7.8M
Evolving Novel AAV Vectors for Gene Therapy to Cure HIVR01AI166969 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI ASOKAN, ARAVIND, SACHA, JONAH B. · 2022 to 2025
$4.9M
A Solid-Phase, Long-Acting CCR5 Monoclonal Antibody for HIV TransmissionR01AI154559 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SACHA, JONAH B. · 2020 to 2024
$4.8M
Discovery and characterization of protective Influenza Type B Virus neuraminidase antibodiesK01OD036063 · OD · VANDERBILT UNIVERSITY · PI Rachael Wolters · 2023 to 2026
$491k
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI129703U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI154559U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI166969U.S. Department of Health & Human Services | NIH | NIH Office of the Director (OD) K01 OD036063
6 · The paper itself

Abstract

Lack of access to antiretroviral therapy (ART) leads to the transmission of human immunodeficiency virus in ~120,000 children annually, emphasizing the need for new strategies to prevent lifelong infection. Here in an infant rhesus macaque model of peripartum oral infection, we show that broadly neutralizing antibodies directed to the viral envelope protein were insufficient to prevent latent reservoir establishment, independent of daily ART. Blockade of the human immunodeficiency virus co-receptor CCR5 via the antibody leronlimab also failed to prevent reservoir establishment, but it significantly reduced reservoir seeding in lymphoid and gastrointestinal tissues. Following the treatment of infants with viraemia at 72 h post-infection with the combination of broadly neutralizing antibodies, ART and leronlimab, no subsequent evidence of replicating or latent virus and antiviral immunity was observed 1 year after treatment interruption. These findings suggest a synergy between broadly neutralizing antibodies, ART and CCR5 blockade for preventing viral reservoir establishment and offer potential improvements over current therapies for newborns exposed to human immunodeficiency virus.

Identifiers

PMID42575974

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.